Effector Therapeutics Executives
| EFTRDelisted Stock | USD 0.13 0.03 30.00% |
Effector Therapeutics employs about 14 people. The company is managed by 7 executives with a total tenure of roughly 33 years, averaging almost 4.0 years of service per executive, having 2.0 employees per reported executive. Discussion of Effector Therapeutics' management performance can provide insight into the enterprise performance.
Effector |
Effector Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.8333) % which means that it has lost $0.8333 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.4656) %, meaning that it created substantial loss on money invested by shareholders. Effector Therapeutics' management efficiency ratios could be used to measure how well Effector Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Effector Therapeutics Workforce Comparison
Effector Therapeutics is rated # 2 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 88.0. Effector Therapeutics retains roughly 14.0 in number of employees claiming about 16% of equities under Health Care industry.
Effector Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Effector Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Effector Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Effector Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Effector Therapeutics Notable Stakeholders
An Effector Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Effector Therapeutics often face trade-offs trying to please all of them. Effector Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Effector Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Stephen Worland | President CEO | Profile | |
| Siegfried Reich | CoFounder Board | Profile | |
| Mayank MD | Chief Officer | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Davide Ruggero | CoFounder Board | Profile | |
| Douglas MD | Chief Officer | Profile | |
| Kevan Shokat | CoFounder Board | Profile |
About Effector Therapeutics Management Performance
The success or failure of an entity such as Effector Therapeutics often depends on how effective the management is. Effector Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Effector management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Effector management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California. Effector Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.
Effector Therapeutics Workforce Analysis
Traditionally, organizations such as Effector Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Effector Therapeutics within its industry.Effector Therapeutics Manpower Efficiency
Return on Effector Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.6M | |
| Net Loss Per Executive | 5.1M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Effector Stock
If you are still planning to invest in Effector Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Effector Therapeutics' history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |